Double Autologous Hematopoietic Stem Cell Transplantation in Hematological Malignancies
10.3969/j.issn.1000-467X.2001.06.019
- VernacularTitle:双次自体造血干细胞移植治疗恶性血液病的临床分析
- Author:
Dong ZHENG
1
;
Cai Guo ZHANG
;
Xun En TAN
;
De Wen HONG
;
Kai Shao LOU
;
Hua Ai PENG
;
Juan LI
;
Zhen Xiu TONG
;
Zhen Feng LAI
Author Information
1. the First Affiliated Hospital Sun Yat sen University of Medical Sciences
- From:Chinese Journal of Cancer
2001;20(6):644-646
- CountryChina
- Language:Chinese
-
Abstract:
Objective：This study was designed to investigate the outcome of double autologous hematopoietic stem cell transplantation(Double AHSCT) in hematological malignancies. Methods: The clinical data of 12 patients who underwent Double AHSCT between January 1995 and January 1999 were analyzed retrospectively and the outcome were compared with that of 17 patients who received single autologous hematopoietic stem cell transplantation (Single AHSCT) in the same period. Results: The duration of continuous remission in 12 patients undergoing Double AHSCT ranged from 6 to 68 months(mean 27 months). Among them, eight patients (66.7％ ) were still alive without relapse up to now. While one patient had relapsed 6 months after second grafting. Three patients died from diseases related to graft. The patients who received Single AHSCT had a continuous remission of 1－ 36 months after graft (mean 12 months). Six of the 17 patients were still alive in good condition. Eight patients relapsed and 3 patients died from diseases related to graft. Conclusion: Good outcome were showed in Double AHSCT for the treatment of hematological malignancies. The 18 month survival rate in Double AHSCT tended to be better than that in Single AHSCT.
